Table 1.
Clinical characteristics before the initiation of first-line treatment in patients who later developed adrenal insufficiency
| Category | N |
|---|---|
| Patients | 5 |
| Median age (range), years | 63 (49–79) |
| Gender, male/female | 3/2 |
| ECOG performance status, 0/1 | 2/3 |
| Smoking history, current plus former/never | 4/1 |
| Histologic subtype, adeno/squamous/not otherwise specified | 3/1/1 |
| Clinical stage (TNM eighth), IVA/IVB/others | 5/0/0 |
| Driver mutation, positive/negative | 0/5 |
| PD-L1 TPS, ≥50/1–49/<1, % | 3/2/0 |
| First-line treatment | |
| Pembrolizumab monotherapy | 2 |
| Carboplatin plus pemetrexed plus pembrolizumab | 1 |
| Carboplatin plus nab-paclitaxel plus pembrolizumab | 2 |
| Best overall response, complete response/partial response | 1/4 |
| Median progression-free survival (95% CI), months | 37.7 (na–na) |
| Median overall survival (95% CI), months | na (na–na) |
ECOG, Eastern Cooperative Oncology Group; TNM, Tumor Nodes Metastasis; PD-L1, programmed cell death ligand-1; TPS, Tumor Proportion Score; CI, confidence interval.